Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.77 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.77 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.77 |
| ▸ | CASP3 | P42574 | 3/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.64 |
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916672 | 0.87 | PTPN7 (0.67) | PTPN7PTPN12PTPN22CASP3SENP8 | |
| SCHEMBL4253115 | 0.83 | PRSS12 (0.67) | PTPN7PTPN12PTPN22CASP3SENP8 | |
| SCHEMBL4249984 | 0.82 | PTPN7 (0.63) | PTPN7PTPN12PTPN22CASP3SENP8 | |
| SCHEMBL4250099 | 0.79 | MAPT (0.70) | PTPN7PTPN12PTPN22SMN1; SMN2NPC1 | |
| SCHEMBL5935569 | 0.77 | MAPT (0.79) | SMN1; SMN2NPC1RAB9AMAPTKMT2A | |
| SCHEMBL30037193 | 0.77 | NPC1 (0.70) | CASP3SENP8SENP7SENP6SMN1; SMN2 | |
| SCHEMBL12768123 | 0.77 | NPC1 (0.70) | CASP3SENP8SENP7SENP6SMN1; SMN2 | |
| SCHEMBL17712419 | 0.77 | RAB9A (0.61) | PTPN7PTPN12PTPN22CASP3SENP8 | |
| SCHEMBL16062688 | 0.77 | NPC1 (1.00) | PTPN7PTPN12PTPN22CASP3SENP8 | |
| SCHEMBL4912955 | 0.77 | DHODH (0.76) | CASP3SENP8SENP7SENP6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | PTPN7 4505/4885PTPN12 4327/4885PTPN22 4307/4885 |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | PTPN7 1146/4885PTPN12 1507/4885PTPN22 1379/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | PTPN7 681/4885PTPN12 1209/4885PTPN22 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.